ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – EW

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Edwards Lifesciences Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Edwards securities between February 6, 2024, and July 24, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 13, 2024 [3]. - The lawsuit claims that during the Class Period, Edwards provided misleading information regarding its expected revenue and the growth of its core product, Transcatheter Aortic Valve Replacement (TAVR) [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering substantial amounts for its clients [4].